Why the study?
Thromboembolism is a major, preventable complication in cancer patients, and the cost-effectiveness and value for money of biomarker risk-directed thromboprophylaxis were evaluated.
Is biomarker risk-directed enoxaparin thromboprophylaxis cost-effective compared to usual care in ambulatory patients with lung and gastrointestinal cancer?
Population
Ambulatory patients with lung and gastrointestinal cancer receiving anticancer therapies
Comparison
Biomarker risk-directed enoxaparin thromboprophylaxis vs usual care (no prophylaxis)
Design
Within-trial and modelled economic evaluation of a phase III randomized trial
Follow-up
5-year horizon
Key result
Biomarker-driven primary thromboprophylaxis in lung and gastrointestinal cancer reduced thromboembolism (HR 0.31, p=0.005) and was cost-effective, saving $1,095 per patient and adding 0.0097 QALYs.
Authors
Loading...
Supports adoption of biomarker-driven enoxaparin thromboprophylaxis in lung and GI cancers; confirms economic dominance alongside RCT efficacy.
RCT
Is biomarker risk-directed enoxaparin thromboprophylaxis cost-effective compared to usual care in ambulatory patients with lung and gastrointestinal cancer?
Effect estimate: HR 0.31
p-value: p=0.005
Biomarker-driven primary thromboprophylaxis in patients with lung and gastrointestinal cancer is cost-saving and more effective than usual care from an Australian healthcare system perspective.
Alexander et al. (2026) conducted an RCT in Ambulatory lung and gastrointestinal cancer. Biomarker risk-directed enoxaparin thromboprophylaxis vs. Usual care (no prophylaxis) was evaluated on Thromboembolism (TE) (HR 0.31, p=0.005). Biomarker-driven primary thromboprophylaxis in lung and gastrointestinal cancer reduced thromboembolism (HR 0.31, p=0.005) and was cost-effective, saving $1,095 per patient and adding 0.0097 QALYs.